A microglia-derived molecular signature identifies FKBP5 as a regulator of neuroinflammatory activation in Alzheimer’s disease

Background Microglial dysfunction is critically involved in Alzheimer’s disease (AD) progression, yet microglia-derived molecular signatures that reflect neuropathological progression and reveal potential therapeutic targets remain incompletely understood. This study aimed to establish a microglia-based risk score model for predicting AD progression and to validate the functional role of model genes in microglial activation. Methods Single-cell RNA sequencing datasets from AD brain tissues were analyzed to characterize disease-associated microglial subpopulations. Weighted gene co-expression network analysis (WGCNA) was performed to identify gene modules associated with Braak neuropathological stages. Microglial marker genes from advanced stage were integrated with Braak-related module genes to identify candidate genes. A least absolute shrinkage and selection operator (LASSO) regression model was constructed to generate a microglia-derived risk score. The relationship between risk score and immune microenvironment features was evaluated. FKBP5 was selected for experimental validation using an Aβ1-42-induced BV2 microglial activation model, followed by molecular docking to explore potential FKBP5-targeting compounds. Results Single-cell transcriptomic analysis revealed neuropathological progression in microglial states during AD progression, with enrichment of activated and immune-related microglial signatures. Integration of microglial markers and Braak-associated WGCNA modules identified 25 overlapping genes involved in immune regulation and microglial function. The LASSO-derived risk score effectively reflected AD progression and was positively associated with microglial activation and immune remodeling. Among the candidate genes, FKBP5 showed increased expression during AD progression and was closely correlated with activated microglial phenotypes. In vitro experiments demonstrated that Aβ1-42 stimulation significantly increased FKBP5 expression and promoted microglial activation via NF-κB signaling, whereas FKBP5 inhibition attenuated activation-related cytokine expression. Molecular docking analysis further suggested potential FKBP5-interacting compounds including Apatinib, Eslicarbazepine acetate, Cefadroxil, Thioisonicotinamide, and Atropine. These computationally predicted interactions warrant further experimental validation to explore their potential pharmacological relevance. Conclusion We developed a microglia-derived molecular risk score that reflects AD neuropathological progression and immune microenvironment remodeling. FKBP5 was identified as a critical regulator of microglial activation and represents a potential therapeutic target for modulating neuroinflammation in AD. These findings provide new insights into microglia-mediated AD progression and establish a framework for integrating single-cell transcriptomics with experimental validation for biomarker and target discovery.

Authors

Institutions

Publication Details

Journal
Frontiers in Molecular Biosciences
Published
2026-11-17
DOI
https://doi.org/10.3389/fmolb.2026.2003525
Primary Topic
Neuroinflammation and Neurodegeneration Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A microglia-derived molecular signature identifies FKBP5 as a regulator of neuroinflammatory activation in Alzheimer’s disease

Shilong Han, Guifang Wen, Zhenqiang Xie
1 links
Frontiers in Molecular Biosciences
Neuroinflammation and Neurodegeneration Mechanisms
article

A microglia-derived molecular signature identifies FKBP5 as a regulator of neuroinflammatory activation in Alzheimer’s disease

Shilong Han, Guifang Wen, Zhenqiang Xie
article en

Abstract

Background Microglial dysfunction is critically involved in Alzheimer’s disease (AD) progression, yet microglia-derived molecular signatures that reflect neuropathological progression and reveal potential therapeutic targets remain incompletely understood. This study aimed to establish a microglia-based risk score model for predicting AD progression and to validate the functional role of model genes in microglial activation. Methods Single-cell RNA sequencing datasets from AD brain tissues were analyzed to characterize disease-associated microglial subpopulations. Weighted gene co-expression network analysis (WGCNA) was performed to identify gene modules associated with Braak neuropathological stages. Microglial marker genes from advanced stage were integrated with Braak-related module genes to identify candidate genes. A least absolute shrinkage and selection operator (LASSO) regression model was constructed to generate a microglia-derived risk score. The relationship between risk score and immune microenvironment features was evaluated. FKBP5 was selected for experimental validation using an Aβ1-42-induced BV2 microglial activation model, followed by molecular docking to explore potential FKBP5-targeting compounds. Results Single-cell transcriptomic analysis revealed neuropathological progression in microglial states during AD progression, with enrichment of activated and immune-related microglial signatures. Integration of microglial markers and Braak-associated WGCNA modules identified 25 overlapping genes involved in immune regulation and microglial function. The LASSO-derived risk score effectively reflected AD progression and was positively associated with microglial activation and immune remodeling. Among the candidate genes, FKBP5 showed increased expression during AD progression and was closely correlated with activated microglial phenotypes. In vitro experiments demonstrated that Aβ1-42 stimulation significantly increased FKBP5 expression and promoted microglial activation via NF-κB signaling, whereas FKBP5 inhibition attenuated activation-related cytokine expression. Molecular docking analysis further suggested potential FKBP5-interacting compounds including Apatinib, Eslicarbazepine acetate, Cefadroxil, Thioisonicotinamide, and Atropine. These computationally predicted interactions warrant further experimental validation to explore their potential pharmacological relevance. Conclusion We developed a microglia-derived molecular risk score that reflects AD neuropathological progression and immune microenvironment remodeling. FKBP5 was identified as a critical regulator of microglial activation and represents a potential therapeutic target for modulating neuroinflammation in AD. These findings provide new insights into microglia-mediated AD progression and establish a framework for integrating single-cell transcriptomics with experimental validation for biomarker and target discovery.

Frontiers in Molecular BiosciencesVol. 13
Dalian Medical University (CN)
Good health and well-being
Neuroinflammation and Neurodegeneration Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon